Incongruent HIV and tuberculosis co-dynamics in Kenya: Interacting epidemics monitor each other

Epidemics

Volumn 1, Issue 1, 2009, Pages 14-20

  Sánchez, María S ^a   Lloyd Smith, James O ^b,c   Williams, Brian G ^d   Porco, Travis C ^e   Ryan, Sadie J ^f   Borgdorff, Martien W ^g,h   Mansoer, John ⁱ   Dye, Christopher ^d   Getz, Wayne M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b PENNSYLVANIA STATE UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d WORLD HEALTH ORGANIZATION   (Switzerland)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f STANFORD UNIVERSITY   (United States)

^g KNCV TUBERCULOSIS FOUNDATION   (Netherlands)

^h UNIVERSITY OF AMSTERDAM   (Netherlands)

ⁱ CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DEMOGRAPHY; DISEASE SURVEILLANCE; DYNAMICS; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; KENYA; MATHEMATICAL MODEL; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SOUTH AFRICA; TUBERCULOSIS; URBANIZATION;

ANTI-RETROVIRAL AGENTS; HIV INFECTIONS; HUMANS; KENYA; MODELS, BIOLOGICAL; PREVALENCE; SENTINEL SURVEILLANCE; TUBERCULOSIS;

EID: 63349107944     PISSN: 17554365     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.epidem.2008.08.001     Document Type: Article

References (56)

1. Abu-Raddad L.J., Patnaik P., and Kublin J.G. Dual infection with HIV and malaria fuels the spread of both diseases in sub-Saharan Africa. Science 314 (2006) 1603-1606
2. Asamoah-Odei E., García-Calleja J.M., and Boerma J.T. HIV prevalence and trends in sub-Saharan Africa: no decline and large subregional differences. Lancet 364 (2004) 35-40
3. Blower S.M., and Dowlatabadi H. Sensitivity and uncertainty analysis of complex-models of disease transmission-an HIV model, as an example. Int. Stat. Rev. 62 (1994) 229-243
4. Brown T., Grassly N.C., Garnett G., and Stanecki K. Improving projections at the country level: the UNAIDS estimation and projection package 2005. Sex. Transm. Infect. 82 (2006) III34-III40
5. Cheluget B., Baltazar G., Orege P., Ibrahim M., Marum L.H., and Stover J. Evidence for population level declines in adult HIV prevalence in Kenya. Sex. Transm. Infect. 82 (2006) I21-I26
6. Corbett E.L., Watt C.J., Walker N., Maher D., Williams B.G., Raviglione M.C., et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch. Intern. Med. 163 (2003) 1009-1021
7. Currie C.S., Williams B.G., Cheng R.C., and Dye C. Tuberculosis epidemics driven by HIV: is prevention better than cure?. AIDS 17 (2003) 2501-2508
8. De Cock K.M., and Chaisson R.E. Will DOTS do it? A reappraisal of tuberculosis control in countries with high rates of HIV infection. Int. J. Tuberc. Lung Dis. 3 (1999) 457-465
9. Dye C. Global epidemiology of tuberculosis. Lancet 367 (2006) 938-940
10. Dye C., Garnett G.P., Sleeman K., and Williams B.G. Prospects for worldwide tuberculosis control under the WHO DOTS strategy. Directly observed short-course therapy. Lancet 352 (1998) 1886-1891
11. Dye C., Watt C.J., Bleed D.M., Hosseini S.M., and Raviglione M.C. Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally. JAMA-J. Am. Med. Assoc. 293 (2005) 2767-2775
12. Fox J., Weber J., and Fidler S. Primary HIV. Sex. Transm. Infect. 82 (2006) 267-268
13. Gagneux S., Burgos M.V., DeRiemer K., Enciso A., Munoz S., Hopewell P.C., et al. Impact of bacterial genetics on the transmission of isoniazid-resistant Mycobacterium tuberculosis. Plos Pathogens 2 (2006) 603-610
14. Gagneux S., DeRiemer K., Van T., Kato-Maeda M., de Jong B.C., Narayanan S., et al. Variable host-pathogen compatibility in Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 2869-2873
15. Gagneux S., Long C.D., Small P.M., Van T., Schoolnik G.K., and Bohannan B.J.M. The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science 312 (2006) 1944-1946
16. García-Calleja J.M., Marum L.H., Carcamo C.P., Kaetano L., Muttunga J., and Way A. Lessons learned in the conduct, validation, and interpretation of national population based HIV surveys. AIDS 19 Suppl. 2 (2005) S9-S17
17. García-Calleja J.M., Gouws E., and Ghys P.D. National population based HIV prevalence surveys in sub-Saharan Africa: results and implications for HIV and AIDS estimates. Sex. Transm. Infect. 82 Suppl. 3 (2006) iii64-iii70
18. Garnett G.P., García-Calleja J.M., Rehle T., and Gregson S. Behavioural data as an adjunct to HIV surveillance data. Sex. Transm. Infect. 82 (2006) I57-I62
19. Garnett G.P., Gregson S., and Stanecki K.A. Criteria for detecting and understanding changes in the risk of HIV infection at a national level in generalised epidemics. Sex. Transm. Infect. 82 (2006) I48-I51
20. Ghys P.D., Kufa E., and George M.V. Measuring trends in prevalence and incidence of HIV infection in countries with generalised epidemics. Sex. Transm. Infect. 82 (2006) I52-I56
21. Githui W.A., Jordaan A.M., Juma E.S., Kinyanjui P., Karimi F.G., Kimwomi J., et al. Identification of MDR-TB Beijing/W and other Mycobacterium tuberculosis genotypes in Nairobi, Kenya. Int. J. Tuberc. Lung Dis. 8 (2004) 352-360
22. Glynn J.R., Kremer K., Borgdorff M.W., Rodríguez M.P., and van Soolingen D. Beijing/W genotype Mycobacterium tuberculosis and drug resistance. Emerg. Infect. Dis. 12 (2006) 736-743
23. Grassly N.C., Fraser C., and Garnett G.P. Host immunity and synchronized epidemics of syphilis across the United States. Nature 433 (2005) 417-421
24. Gregson S., Garnett G.P., Nyamukapa C.A., Hallett T.B., Lewis J.J., Mason P.R., et al. HIV decline associated with behavior change in eastern Zimbabwe. Science 311 (2006) 664-666
25. Hallett T.B., Aberle-Grasse J., Boulos L.M., Cayemittes M.P.A., Cheluget B., Chipeta J., et al. Declines in HIV prevalence can be associated with changing sexual behaviour in Uganda, urban Kenya, Zimbabwe, and urban Haiti. Sex. Transm. Infect. 82 (2006) I1-I8
26. Hanson C., and Kibuga D. Effective tuberculosis control and health sector reforms in Kenya: challenges of an increasing tuberculosis burden and opportunities through reform. Int. J. Tuberc. Lung Dis. 4 (2000) 627-632
27. Lan N.T.N., Lien H.T.K., Tung L.B., Borgdorff M.W., Kremer K., and van Soolingen D. Mycobacterium tuberculosis Beijing genotype and risk for treatment failure and relapse, Vietnam. Emerg. Infect. Dis. 9 (2003) 1633-1635
28. Lawn S.D., and Wilkinson R. Extensively drug resistant tuberculosis. BMJ 333 (2006) 559-560
29. Lawn S.D., Bekker L.G., Middelkoop K., Myer L., and Wood R. Impact of HIV infection on the epidemiology of tuberculosis in a peri-urban community in South Africa: the need for age-specific interventions. Clin. Infect. Dis. 42 (2006) 1040-1047
30. López B., Aguilar D., Orozco H., Burger M., Espitia C., Ritacco V., et al. A marked difference in pathogenesis and immune response induced by different Mycobacterium tuberculosis genotypes. Clin. Exp. Immunol. 133 (2003) 30-37
31. Mahomva A., Greby S., Dube S., Mugurungi O., Hargrove J., Rosen D., et al. HIV prevalence and trends from data in Zimbabwe, 1997-2004. Sex. Transm. Infect. 82 Suppl. 1 (2006) i42-i47
32. Malik A.N., and Godfrey-Faussett P. Effects of genetic variability of Mycobacterium tuberculosis strains on the presentation of disease. Lancet, Infect. Dis. 5 (2005) 174-183
33. Mansoer, J., Scheele, S., Floyd, K., Dye, C., Sitienei, J., Williams, B.G., New Methods for Estimating the Tuberculosis Case Detection Rate in High-HIV Prevalence Countries: The Example of Kenya. Bulletin of the World Health Organization, in press.
34. Marais B.J., Victor T.C., Hesseling A.C., Barnard M., Jordaan A., Brittle W., et al. Beijing and Haarlem genotypes are overrepresented among children with drug-resistant tuberculosis in the Western Cape Province of South Africa. J. Clin. Microbiol. 44 (2006) 3539-3543
35. Morgan D., Mahe C., Mayanja B., Okongo J.M., Lubega R., and Whitworth J.A.G. HIV-1 infection in rural Africa: is there a difference in median time to AIDS and survival compared with that in industrialized countries?. AIDS 16 (2002) 597-603
36. Morgan M., Walker N., Gouws E., Stanecki K.A., and Stover J. Improved plausibility bounds about the 2005 HIV and AIDS estimates. Sex. Transm. Infect. 82 (2006) III71-III77
37. Murphy E.M., Greene M.E., Mihailovic A., and Olupot-Olupot P. Was the "ABC" approach (abstinence, being faithful, using condoms) responsible for Uganda′s decline in HIV?. PLoS Med. 3 (2006) e379
38. Murray C.J., and Salomon J.A. Modeling the impact of global tuberculosis control strategies. Proc. Natl. Acad. Sci. U. S. A 95 (1998) 13881-13886
39. Noymer A., and Garenne M. The 1918 influenza epidemic′s effects on sex differentials in mortality in the United States. Popul. Dev. Rev. 26 (2000) 565-581
40. Nunn P., Williams B., Floyd K., Dye C., Elzinga G., and Raviglione M. Tuberculosis control in the era of HIV. Nat. Rev. Immunol. 5 (2005) 819-826
41. Odhiambo J.A., Borgdorff M.W., Kiambih F.M., Kibuga D.K., Kwamanga D.O., Ng'ang'a L., et al. Tuberculosis and the HIV epidemic: increasing annual risk of tuberculous infection in Kenya, 1986-1996. Am. J. Public Health 89 (1999) 1078-1082
42. Pinkerton S.D., Layde P.M., DiFranceisco W., and Chesson H.W. All STDs are not created equal: an analysis of the differential effects of sexual behaviour changes on different STDs. Int. J. STD AIDS 14 (2003) 320-328
43. Salomon J.A., Lloyd-Smith J.O., Getz W.M., Resch S., Sánchez M.S., Porco T.C., et al. Prospects for advancing tuberculosis control efforts through novel therapies. PLoS Med. 3 (2006) e273
44. Sánchez M.S., Lloyd-Smith J.O., Porco T.C., Williams B.G., Borgdorff M.W., Mansoer J., et al. Impact of HIV on novel therapies for tuberculosis control. AIDS 22 (2008) 963-972
45. Shelton J.D., Halperin D.T., and Wilson D. Has global HIV incidence peaked?. Lancet 367 (2006) 1120-1122
46. Sonnenberg P., Glynn J.R., Fielding K., Murray J., Godfrey-Faussett P., and Shearer S. How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners. J. Infect. Dis. 191 (2005) 150-158
47. UNAIDS, UNAIDS Annual Report: 2006 Report on the global AIDS epidemic: A UNAIDS 10th anniversary special edition. Geneva, 2006.
48. UNAIDS, 2008 Report on the global AIDS epidemic. Geneva, 2008.
49. Walker N., Stanecki K.A., Brown T., Stover J., Lazzari S., García-Calleja J.M., et al. Methods and procedures for estimating HIV/AIDS and its impact: the UNAIDS/WHO estimates for the end of 2001. AIDS 17 (2003) 2215-2225
50. Walker N., Grassly N.C., Garnett G.P., Stanecki K.A., and Ghys P.D. Estimating the global burden of HIV/AIDS: what do we really know about the HIV pandemic?. Lancet 363 (2004) 2180-2185
51. Wandel S., Egger M., Rangsin R., Nelson K.E., Costello C., Lewden C., et al. Duration from seroconversion to eligibility for antiretroviral therapy and from ART eligibility to death in adult HIV-infected patients from low and middle-income countries: collaborative analysis of prospective studies. Sex. Transm. Infect. 84 Suppl. 1 (2008) i31-i36
52. White R.G., Orroth K.K., Korenromp E.L., Bakker R., Wambura M., Sewankambo N.K., et al. Can population differences explain the contrasting results of the Mwanza, Rakai, and Masaka HIV/sexually transmitted disease intervention trials? A modeling study. J. Acquir. Immune Defic. Syndr. 37 (2004) 1500-1513
53. Williams B.G., and Dye C. Antiretroviral drugs for tuberculosis control in the era of HIV/AIDS. Science 301 (2003) 1535-1537
54. Williams B.G., Granich R., Chauhan L.S., Dharmshaktu N.S., and Dye C. The impact of HIV/AIDS on the control of tuberculosis in India. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 9619-9624
55. World Health Organization. Global Tuberculosis Control: Surveillance, Planning, Financing: WHO report 2006 (2006), World Health Organization, Geneva
56. World Health Organization. WHO Global TB Database (2006). http://www.who.int/tb/country/global_tb_database/en/index.html Available at: http://www.who.int/tb/country/global_tb_database/en/index.html